Partner Headlines - LLY

  1. Benzinga's Top Initiations

    Benzinga
  2. U.S. District Court Rules in Lilly's Favor on Alimta Vitamin ...

    Benzinga
  3. Benzinga's Volume Movers

    Benzinga
  4. Lilly Issues Update on Evacetrapib Phase 3 Trial: Last Patient ...

    Benzinga
  5. Biogen's Big-Volume Plunge Marks End Of 5-Year Run

    IBD
  6. Valeant Posts Princely Gains

    IBD
  7. 3 Big-Cap Drugmakers Who Beat Q2 Earnings Estimates

    IBD
  8. Shire Lifts 2015 Guidance On Strong Drug Pipeline

    IBD
  9. Lilly, Bristol-Myers Beat Q2 Views, Lift Guidance

    IBD
  10. Valeant Earnings Soar On M&A, Organic Sales Growth

    IBD
  11. Wall Street Struggles for Direction After Two-Day Selloff

    FoxBusiness
  12. Alzheimer's Data Diverge

    IBD
  13. Biogen, Lilly Alzheimer's Data Spark Street Debate

    IBD
  14. Are We Any Closer to Finding a Drug to Battle Alzheimer's?

    FoxBusiness
  15. Data Using New Delayed-Start Methodology Suggested Benefit of ...

    Benzinga
  16. Fast Money Picks For July 21

    Benzinga
  17. 6 Big-Cap Drugmakers Reporting Earnings Next Week

    IBD
  18. Celgene Hits High As Street Applauds Receptos Buyout

    IBD
  19. Manning & Napier Advisors' Most Weighted Trades in Q2 2015

    GuruFocus
  20. Weekly 52-Week Highs Highlight: LLY, PLL, SBUX, VLO

    GuruFocus
  21. Eli Lilly Shares Go Parabolic

    Benzinga
  22. Stocks Cling To Thin Early Gains; Ambarella Bounces, Cree Dives

    IBD
  23. Alder Bio Up As Credit Suisse Lauds Migraine Drug

    IBD
  24. Bristol-Myers Squibb Takes A Step Up On Cancer Drugs, But The ...

    GuruFocus
  25. Where Can Mega-Drug Stock Gilead Sciences Go Now?

    IBD
  26. Teva Migraine Drug Succeeds In Midstage Trial

    IBD
  27. Teva Migraine Drug Succeeds In Midstage Trial

    IBD
  28. Benzinga's Top Initiations

    Benzinga
  29. Activist Hedge Fund Manager Has Strong Focus on Health Care Stocks

    GuruFocus
  30. New Migraine Drugs Could Ease Investors' Headaches

    IBD
  31. What We Don't Know About Antibiotics Could Kill Us

    FoxBusiness
  32. ImmunoGen Surprises, PD-1 Drugs Under Scrutiny At ASCO

    IBD
  33. 4 Stocks Rising On ASCO Cancer Drug News

    IBD
  34. Bristol Sinks On Lung Cancer Data; Merck Up On 2 Trials

    IBD
  35. Lilly and Incyte Announce Webcast to Discuss Baricitinib Phase ...

    Benzinga
  36. Lilly to Present New Clinical Data at 75th American Diabetes ...

    Benzinga
  37. Amgen Down After Suicides Kill AstraZeneca Deal

    IBD
  38. IPO Stock Watch: Alder Soars On Migraine Drug Results

    IBD
  39. Vanguard Adds to Four of Its Largest Stakes

    GuruFocus
  40. Biogen Making A Breakthrough In Treating Alzheimer's

    GuruFocus
  41. 8 Dividend Stocks With The Right Qualities

    GuruFocus
  42. MannKind Looks Good For Long Term Investors

    GuruFocus
  43. Citigroup Upgrades Eli Lilly To Buy

    Benzinga
  44. Novartis EPS beats the Street

    IBD
  45. Eli Lilly

    IBD
  46. US Stock Futures Down Ahead Of Earnings, Economic Data

    Benzinga
  47. Eli Lilly Tops Q1 Views

    Benzinga
  48. Eli Lilly Partner Deciphera Pharma Announces Data Highlighting ...

    Benzinga
  49. AstraZeneca's Onglyza Ups Risk Of Death, FDA Says

    IBD
  50. 5 'Key Pipeline Catalysts' To Watch At Eli Lilly

    Benzinga
  51. Can Veeva Systems' Software Keep Luring Big Pharma?

    IBD
  52. IPO Alert: Biotech Investors Should Watch Advanced Accelerator's ...

    Benzinga
  53. UBS: Eli Lilly's 'Outlook Continuing To Improve'

    Benzinga
  54. Eli Lilly CEO Explains The Reasons Behind Not Changing 2015 Guidance ...

    Benzinga
  55. Viekira Pak View Falls Short

    IBD
  56. AbbVie Beats, But Stock Falls; Lilly Cuts Guidance

    IBD
  57. UPDATE: Eli Lilly Posts Upbeat Q4 Profit, Sales Decline

    Benzinga
  58. Earnings Scheduled For January 30, 2015

    Benzinga
  59. 10 Must Watch Stocks for Today

    Benzinga
  60. Box Ready To Unwrap IPO In Hot Online Storage Field

    IBD
  61. Feeling Good With This Med Company

    GuruFocus
  62. Eli Lilly

    IBD
  63. Here Is Goldman Sachs' Potential Pair Trade For 2 Drug Giants

    Benzinga
  64. 10 Biotech Stories You Might've Missed This Week

    Benzinga
  65. Eli Lilly Has 'Turned The Corner,' Upgraded

    IBD
  66. Exclusive: JPMorgan Chase CEO Jamie Dimon Talks Cancer Recovery, ...

    FoxBusiness
  67. Eil Lilly CEO Talks New Product Launches, Pricing Pressure From ...

    Benzinga
  68. FDA Issues Import Block On Eli Lilly's Cialis

    Benzinga
  69. Biotechs Presenting At The J.P. Morgan Healthcare Conference: ...

    Benzinga
  70. Deutsche Bank, Stifel Differ On Outlook For Eli Lilly

    Benzinga
  71. Benzinga's Top Upgrades

    Benzinga
  72. Jefferies Upgrades Eli Lilly To Buy

    Benzinga
  73. UPDATE: Deutsche Bank Downgrades Eli Lilly On Positive Outlook, ...

    Benzinga
  74. Eli Lilly

    IBD
  75. Alkermes Hits High On Schizophrenia Drug Results

    IBD
  76. Eli Lilly Moves Higher Following FY 2014 & 2015 Outlook

    Benzinga
  77. Benzinga's Top #PreMarket Losers

    Benzinga
  78. Fast Money Halftime Report Final Trade From January 6

    Benzinga
  79. US Stock Futures Surge Ahead Of Manufacturing Data

    Benzinga
  80. Roche Drugs For Alzheimer's, Breast Cancer Disappoint

    IBD
  81. 7 Stocks You Should Be Watching Today

    Benzinga
  82. Eli Lilly

    IBD
  83. Lilly Upgraded On 2 Potential Blockbuster Drugs

    IBD
  84. Alexandria Real Estate REIT Inks Rx For Pharma Boom

    IBD
  85. Biogen Alzheimer's Drug Succeeding In Early Tests

    IBD
  86. Zosano Pharma and Eli Lilly and Company Enter Into Exclusive ...

    Benzinga
  87. Sanofi's Bullish Pipeline Forecast Underwhelms Street

    IBD
  88. Screening Pharma Stocks Amid Turnaround

    YCharts
  89. Sarah Ketterer Dives in when Others Pull Out

    GuruFocus
  90. Credit Suisse Raises Eli Lilly Price Target

    Benzinga
  91. Veeva Systems Flies High On Cloud For Life Sciences

    IBD
  92. Sanofi Axes CEO, Hit By Multiple Downgrades

    IBD
  93. French Drugmaker Sanofi Warns Of Tougher Competition

    IBD
  94. US Stock Futures Rise Ahead Of Earnings, Economic Data

    Benzinga
  95. Earnings Scheduled For October 23, 2014

    Benzinga
  96. CANDA NK-2 Files Motion To Dismiss Patent Infringement Suit

    Benzinga
  97. Lilly, Zymeworks Announce Expansion Of Strategic Licensing And ...

    Benzinga
  98. Benzinga Weekly Preview: Earnings Season Is In Full Swing

    Benzinga
  99. Celgene, Alexion Among 4 IBD 50 Medical s To Report

    IBD
  100. UPDATE: Lilly To Initiate Efforts To Sell Guayama Site

    Benzinga
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!